Comparison of Survival by Multimodal Treatment Regimen Among Malignant Pleural Mesothelioma Patients in an Integrated Health System

Clinical Lung Cancer 2022 December [Link] Kian C Banks, Stephanie Ossowski, Yun-Yi Hung, Diana S Hsu, Simon K Ashiku, Ashish R Patel, Jeffrey B Velotta, J Marie Suga Abstract Background: Optimal therapy for malignant pleural mesothelioma (MPM) remains unclear. We compared overall survival in patients with MPM after various multimodal treatment regimens including combinations of…

Read More

Butein-instigated miR-186-5p-dependent modulation of TWIST1 affects resistance to cisplatin and bioenergetics of Malignant Pleural Mesothelioma cells

Cancer Drug Resistance 2022 July 3 [Link] Mario Cioce, Daniela Rutigliano, Annamaria Puglielli, Vito Michele Fazio Abstract Aim: Malignant pleural mesothelioma is a chemoresistant tumor, and biphasic and sarcomatoid histologies portend the worst prognosis for malignant pleural mesothelioma (MPM) patients. We obtained the microRNA expression profile of three biphasic-sarcomatoid MPM cell lines to identify commonly…

Read More

Expression of phosphorylated ribosomal protein S6 in mesothelioma patients – correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project

Modern Pathology 2022 September 17 [Link] Jan Hendrik Rüschoff, Martina Haberecker, Zoi Tsourti, Kristiaan Nackaerts, Marc de Perrot, Luka Brcic, Ernest Nadal, Sotirios Tsimpoukis, Steven G Gray, Luca Ampollini, Joachim G Aerts, Emanuela Felley-Bosco, Michaela B Kirschner, Kim Monkhorst, Birgit Weynand, Fatemeh Bavaghar-Zaeimi, Miroslav Samarzija, Roger Llatjos, Stephen P Finn, Enrico Silini, Jan von der…

Read More

Hypothesis: HEG1 and claudin-4 staining will allow a diagnosis of epithelioid and biphasic mesothelioma versus non-small-cell lung carcinoma with only two stains in most cases

Histopathology 2022 August 25 [Link] Andrew Churg, Julia R Naso Abstract Separation of mesothelioma from metastatic carcinoma requires immunohistochemical support, with small batteries of stains recommended as a starting-point, but these numbers commonly expand to 10, 12 or more stains, a process that is not only expensive but frequently generates anomalous or confounding results, leading…

Read More

FDG PET/CT for Staging and Restaging Malignant Mesothelioma

Seminars in Nuclear Medicine 2022 August 11 [Link] Egesta Lopci, Angelo Castello, Luigi Mansi Abstract Malignant mesothelioma is an aggressive tumor originating from the mesothelial cells and presenting in general with a very poor prognosis. The pleural localization represents the prevailing disease site, while peritoneal involvement is commonly rare. The WHO classifies mesotheliomas into epithelioid,…

Read More

Diagnostic capacity of BAP1 and MTAP in cytology from effusions and biopsy in mesothelioma

Journal of the American Society of Cytopathology 2022 July 9 [Link] Louise Andersen Lynggård, Vasiliki Panou, Weronika Szejniuk, Oluf Dimitri Røe, Christos Meristoudis Abstract Introduction: Serous effusion is often the first sign of mesothelioma. Diagnosis based on cytologic material from the effusions remains controversial and complementary biopsy is usually required. However, obtaining representative tissue sample…

Read More

Combined treatment with inhibitors of ErbB Receptors and Hh signaling pathways is more effective than single treatment in reducing the growth of malignant mesothelioma both in vitro and in vivo

Journal of Translational Medicine 2022 June 25 [Link] Roberto Bei, Monica Benvenuto, Chiara Focaccetti, Sara Fazi, Marta Moretti, Daniela Nardozi, Valentina Angiolini, Sara Ciuffa, Loredana Cifaldi, Raffaele Carrano, Camilla Palumbo, Martino Tony Miele, Riccardo Bei, Giovanni Barillari, Vittorio Manzari, Enrico De Smaele, Andrea Modesti, Laura Masuelli Abstract Malignant mesothelioma (MM) is a rare orphan aggressive…

Read More

BAP1 and Claudin-4, But Not MTAP, Reliably Distinguish Borderline and Low-grade Serous Ovarian Tumors From Peritoneal Mesothelioma

International Journal of Gynecological Pathology 2022 March 29 [Link] Kyle M Devins, Lawrence Zukerberg, Jaclyn C Watkins, Yin Pun Hung, Esther Oliva Abstract Peritoneal mesothelioma (PM) and serous neoplasms can be difficult to differentiate, particularly in small biopsies. BRCA1-associated protein 1 (BAP1) is expressed in benign tissues, but over 50% of PMs demonstrate complete loss…

Read More

Dissecting and Reconstructing Matrix in Malignant Mesothelioma Through Histocell-Histochemistry Gradients for Clinical Applications

Frontiers in Medicine 2022 April 13 [Link] Marcelo Luiz Balancin, Camila Machado Baldavira, Tabatha Gutierrez Prieto, Juliana Machado-Rugolo, Cecília Farhat, Aline Kawassaki Assato, Ana Paula Pereira Velosa, Walcy Rosolia Teodoro, Alexandre Muxfeldt Ab’Saber, Teresa Yae Takagaki, Vera Luiza Capelozzi Abstract Background: Malignant pleural mesotheliomas (MM) are known for their heterogenous histology and clinical behavior. MM…

Read More

Expression of PD-L1 in Patients With Malignant Peritoneal Mesothelioma: A Pilot Study

The Journal of Surgical Research 2022 April 27 [Link] Victor P Gazivoda, Aaron W Kangas-Dick, Alissa A Greenbaum, Joshua Roshal, Chunxia Chen, Dirk F Moore, Russell C Langan, Timothy J Kennedy, Christine Minerowicz, H Richard Alexander Abstract Introduction: Frequency of PD-L1 expression and the role of immunotherapy in malignant peritoneal mesothelioma (MPM) have not been…

Read More